Literature DB >> 33135241

Covid-19 positivity affects outcome of cardiac surgical patients.

Anastasia Katsiampoura1, Cesar Perozo1, Andreas Varkaris2, Sandhya Vellayappan1, Ming Zhen Tam1, Usha Vellayappan1, Arvind Agnihotri3, Stanley Tam3.   

Abstract

INTRODUCTION: In this report we describe the clinical presentation, laboratory findings and outcomes of four patients that were referred for urgent cardiothoracic intervention and tested positive for COVID-19.
METHODS: The St. Elizabeth's Medical Center Institutional Review Board exempted the study from review (waived review). In each case, verbal informed consent was obtained by the study participant or health care proxy.
RESULTS: The majority of the patients undergoing surgery had low Society of Thoracic Surgeons score and uneventful operating time. The mortality was very high and driven primarily by the viral syndrome. Laboratory markers that have been associated with disease severity in the general population were also prognostic in our population.
CONCLUSION: Our study shows that these patients have very high mortality, whereas prevention and preoperative screening is required in preventing nosocomial spreading of the disease.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; cardiac surgery; inflammatory markers; perioperative management

Year:  2020        PMID: 33135241     DOI: 10.1111/jocs.14982

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  2 in total

1.  COVID-19 Positive Cohort Undergoing Cardiac Surgery: A Possible Un(3H)oly Trinity of Hypoxia-Hemolysis-Hyperinflammation.

Authors:  Rohan Magoon; Ramesh Kashav; Jes Jose; Ashish Walian; Souvik Dey
Journal:  Braz J Cardiovasc Surg       Date:  2022-08-16

2.  The influence of SARS-CoV-2 vaccination on post-operative outcomes in microsurgery patients.

Authors:  Susan M Taghioff; Benjamin R Slavin; Manish Narasimman; Georges Samaha; Mario Samaha; Tripp Holton; Devinder Singh
Journal:  Microsurgery       Date:  2022-07-15       Impact factor: 2.080

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.